Why Outlook Therapeutics Inc (OTLK) Stock Is Rising
As of 2026-08-25, Outlook Therapeutics Inc (OTLK) has a next-year EPS growth estimate of 61.11%. Featured in 4 EPS revision reports, most recently on 2026-06-22.
Why OTLK Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Outlook Therapeutics Inc's next-year EPS growth estimate from 54.49% to 61.11% on 2026-08-19.
- ·Current-Year Growth: Projected at 72.35%, supporting the forward estimate revision.
News Context
The primary structural driver is the analysts’ upgrade of next-year EPS growth from 54.49% to 61.11% on 2026-08-19. That revision was plausibly catalyzed by the FDA approval of LYTENAVA for wet AMD, followed by a product launch and bullish commentary on its potential in the $8.5B U.S. retina market. The upward move has continued past the initial revision, supported by strong Q3 FY2026 results and sustained analyst enthusiasm.
Generated 2026-08-25 · news as of 2026-08-25
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 61.11%
- EPS growth this year
- 72.35%
- EPS next quarter (est)
- -$0.07
- Last price
- $0.64
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-25 | 61.11% | 72.35% | -$0.07 | $0.64 |
| 2026-08-24 | 61.11% | 72.35% | -$0.07 | $0.61 |
| 2026-08-23 | 61.11% | 72.35% | -$0.07 | $0.65 |
| 2026-08-21 | 61.11% | 72.35% | -$0.07 | $0.65 |
| 2026-08-20 | 61.11% | 72.35% | -$0.07 | $0.68 |
| 2026-08-19 | 61.11% | 72.35% | -$0.07 | $0.69 |
| 2026-08-18 | 54.49% | 70.95% | -$0.07 | $0.70 |
| 2026-08-17 | 54.49% | 70.95% | -$0.07 | $0.67 |
| 2026-08-16 | 54.49% | 70.95% | -$0.07 | $0.76 |
| 2026-08-14 | 54.49% | 70.95% | -$0.07 | $0.76 |
| 2026-08-13 | 59.15% | 73.56% | -$0.08 | $0.89 |
| 2026-08-12 | 59.15% | 73.56% | -$0.08 | $1.10 |
| 2026-08-11 | 59.15% | 73.56% | -$0.08 | $1.13 |
| 2026-08-10 | 59.15% | 73.56% | -$0.08 | $1.15 |
| 2026-08-09 | 59.15% | 73.56% | -$0.08 | $1.02 |
| 2026-08-07 | 59.15% | 73.56% | -$0.08 | $1.02 |
| 2026-08-06 | 59.15% | 73.56% | -$0.08 | $0.97 |
| 2026-08-05 | 59.15% | 73.56% | -$0.08 | $1.03 |
| 2026-08-04 | 59.15% | 73.56% | -$0.08 | $0.96 |
| 2026-08-03 | 63.54% | 73.18% | -$0.09 | $0.91 |
| 2026-08-02 | 63.54% | 73.18% | -$0.09 | $0.98 |
| 2026-07-31 | 63.54% | 73.18% | -$0.09 | $0.98 |
| 2026-07-30 | 63.54% | 73.18% | -$0.09 | $1.04 |
| 2026-07-29 | 63.54% | 73.18% | -$0.09 | $1.00 |
| 2026-07-28 | 63.54% | 73.18% | -$0.09 | $0.90 |
| 2026-07-27 | 63.54% | 73.18% | -$0.09 | $1.07 |
| 2026-07-26 | 46.28% | 72.02% | -$0.11 | $1.40 |
| 2026-07-24 | 46.28% | 72.02% | -$0.11 | $1.40 |
| 2026-07-23 | 46.28% | 72.02% | -$0.11 | $1.32 |
| 2026-07-22 | 46.28% | 72.02% | -$0.11 | $1.34 |
Reports Featuring OTLK
- 2026-06-22
Top EPS Revision Winners: OTLK Surges 66%, FTH Gains 60% on Estimate Hikes
- 2026-06-18
OTLK Surges 43.6% on FDA News; WDC +41%, FCEL +37.5% Lead EPS Revision Movers
- 2026-06-17
Outlook Therapeutics Soars 50% as EPS Revision and FDA Acceptance Fuel Rally
- 2026-06-16
OTLK, WDC Lead EPS Revision Winners: +42.7% and +33.1% Gains
Recent News
- Outlook Therapeutics, Inc. Q3 2026 Earnings Call SummaryMoby
- Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVAGlobeNewswire
- Outlook Therapeutics Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIGStocktwits
- Outlook Therapeutics wins FDA approval for Lytenava in wet AMDPharmaceutical Technology
- Outlook Therapeutics shares climb after FDA clears LYTENAVA for wet AMDInvestorsHub
- FDA scientists question Capricor data; Legend CEO steps downBioPharma Dive
- OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug Analysts See Nearly 300% UpsideStocktwits
- FDA Showdown Week: CAPR, NRXP, REPL And MRNA Face Make-Or-Break Regulatory DecisionsStocktwits
- OTLK Stock Surges After FDA Ends Decade-Long Wait For Ophthalmic BevacizumabStocktwits
- Outlook Therapeutics Announces LYTENAVA FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMDGlobeNewswire
Screen Performance
Aggregate stats across all 2014 tickers our top-EPS-revision screen has flagged over the past 146 days.
- Median return since detection
- +3.1%
- % of tickers in the green
- 56%
- Median return on winners
- +19.9%
- Large revisions captured
- 1606
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Outlook Therapeutics Inc (OTLK) stock go up recently?▾
Outlook Therapeutics Inc (OTLK) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 54.49% to 61.11% on 2026-08-19. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Outlook Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-08-25, Outlook Therapeutics Inc (OTLK) has a next-year EPS growth estimate of 61.11%, based on analyst consensus.
When was the latest EPS estimate revision for OTLK?▾
The most recent revision occurred on 2026-08-19, when analysts adjusted the next-year EPS growth estimate from 54.49% to 61.11%.
What sector and industry does Outlook Therapeutics Inc belong to?▾
Outlook Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. OTLK appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Outlook Therapeutics Inc (OTLK) appears here because it was detected by our daily top-EPS-revision-performer screen.